Clinical trial · Interventional
Cervix Hypoxia FAZA
A Feasibility Study of Hypoxia Imaging in Patients With Cervix Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to look for low levels of oxygen (hypoxia) in your cervix cancer using a special x-ray test called a positron emission tomography (PET)scan. Hypoxia may have an effect on how cervix cancer grows and responds to treatments like radiotherapy and chemotherapy. Doctors at Princess Margaret Hospital have measured hypoxia in over 300 patients. The use of PET scans to measure hypoxia may be better and simpler than the methods used previously.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervix Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-Fluoroazomycin Arabinoside (18F-FAZA) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET FAZA imaging
- description
- PET FAZA imaging of tumor hypoxia in patients with cervix cancer
- interventionNames
- Procedure: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Primary outcomes (1)
- measure
- Number of patients treated with the PET tracer FAZA to image primary tumor hypoxia in patients with cervix cancer prior to treatment with radiotherapy and concurrent cisplatin chemotherapy
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * Histologic diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix * TNM (7th edition) cT1-4, N0-1, M0-1 * Intention to treat using radiotherapy with or without concurrent cisplatin chemotherapy according to the current treatment policies of the PMH Gynecology Group * No cytotoxic anti-cancer therapy for cervix cancer prior to study entry * A negative urine or serum pregnancy test within the two week interval immediately prior to PET-CT imaging, in women of child-bearing age * Ability to provide written informed consent to participate in the study Exclusion Criteria: * Prior complete or partial hysterectomy * Carcinoma of the cervical stump * Inability to lie supine for more than 30 minutes * Patients taking the drug disulfuram (Antabuse)
References
Publications (0)
Data not yet available